Stemline Therapeutics (STML) Upgraded to “Hold” at ValuEngine

Stemline Therapeutics (NASDAQ:STML) was upgraded by ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Friday.

A number of other research firms have also weighed in on STML. Cowen restated a “buy” rating on shares of Stemline Therapeutics in a report on Tuesday, October 31st. HC Wainwright upped their target price on Stemline Therapeutics from $34.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday, November 1st. BidaskClub lowered Stemline Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. Finally, Zacks Investment Research upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, January 5th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $33.75.

Shares of Stemline Therapeutics (STML) remained flat at $$15.85 during trading hours on Friday. The company had a trading volume of 356,867 shares, compared to its average volume of 333,311. Stemline Therapeutics has a 1 year low of $5.80 and a 1 year high of $17.40. The company has a market cap of $400.80, a P/E ratio of -6.17 and a beta of -0.02.

Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.11). Stemline Therapeutics had a negative return on equity of 75.50% and a negative net margin of 4,689.63%. sell-side analysts predict that Stemline Therapeutics will post -2.68 EPS for the current fiscal year.

In other Stemline Therapeutics news, COO Kenneth Hoberman sold 11,943 shares of the company’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $14.18, for a total transaction of $169,351.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider David Gionco sold 4,250 shares of the company’s stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $13.43, for a total value of $57,077.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 42,216 shares of company stock valued at $591,925. 16.70% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of STML. Voya Investment Management LLC purchased a new stake in shares of Stemline Therapeutics during the 2nd quarter valued at $102,000. Nationwide Fund Advisors lifted its holdings in shares of Stemline Therapeutics by 7.2% during the 2nd quarter. Nationwide Fund Advisors now owns 12,755 shares of the biopharmaceutical company’s stock valued at $117,000 after purchasing an additional 855 shares during the last quarter. Alliancebernstein L.P. purchased a new stake in shares of Stemline Therapeutics during the 2nd quarter valued at $178,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Stemline Therapeutics by 40.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,279 shares of the biopharmaceutical company’s stock valued at $178,000 after purchasing an additional 5,522 shares during the last quarter. Finally, Rhumbline Advisers lifted its holdings in shares of Stemline Therapeutics by 18.5% during the 2nd quarter. Rhumbline Advisers now owns 27,358 shares of the biopharmaceutical company’s stock valued at $252,000 after purchasing an additional 4,280 shares during the last quarter. Institutional investors own 50.27% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/02/04/stemline-therapeutics-stml-upgraded-to-hold-at-valuengine.html.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply